Hodgkin'S Lymphoma Clinical Trials
Here are the 6 most popular medical studies for hodgkin's lymphoma
Stem Cell Transplant
Bone Marrow/Kidney Transplant for Blood Disorders & Chronic Kidney Disease
This trial is for a combined bone marrow and kidney transplant from a partially matched related donor to treat a blood disorder and kidney disease. The expectation is to have 10 people participate.
CAR T-cell Therapy
TAA-Specific CTL Therapy for Lymphoma
This trial is for patients who have a type of lymph gland disease called Hodgkin or non-Hodgkin lymphoma which has come back, or may come back, or has not gone away after treatment. This is a research study using special immune system cells called tumor associated antigen (TAA)-specific cytotoxic T lymphocytes, a new experimental therapy.
AH-HA EHR Tool for Heart Health in Cancer Survivors
This trial is looking at the effects of a tool that uses electronic health records to help cancer survivors manage their cardiovascular health. The study will compare how well the tool works compared to usual care in terms of risk reduction and health promotion activities.
Popular filter options for hodgkin's lymphoma trials
Diffuse Large B-Cell Lymphoma Clinical Trials
View 50 Diffuse Large B-Cell Lymphoma medical studies.
Janus Kinase Inhibitor
Itacitinib for Graft-versus-Host Disease Prevention
This trial is testing whether a drug that inhibits Janus kinase 1 (JAK1) can help reduce graft-versus-host-disease (GVHD) and cytokine release syndrome (CRS) while still retaining the benefits of graft-versus-leukemia (GVL) and improving engraftment.
Monoclonal Antibodies
Favezelimab + Pembrolizumab for Lymphoma
This trial will study the safety and effectiveness of two drugs, favezelimab and pembrolizumab, when used alone or in combination to treat people with classical Hodgkin lymphoma, diffuse large B-cell lymphoma, and indolent non-Hodgkin lymphoma.
CAR T-cell Therapy
Cytotoxic T Cells for Lymphoma
This trial is testing whether a new experimental therapy, third party LMP specific cytotoxic T lymphocytes (CTLs), can prevent or treat EBV Disorder including either Hodgkin Lymphoma or non-Hodgkin Lymphoma or Lymphoepithelioma or severe chronic active EBV infection syndrome (SCAEBV) or Leiomyosarcoma which has come back or has not gone away after treatment, including the best treatment.
Non-Hodgkin's Lymphoma Clinical Trials
View 47 Non-Hodgkin's Lymphoma medical studies.
Janus Kinase Inhibitor
Itacitinib for Graft-versus-Host Disease Prevention
This trial is testing whether a drug that inhibits Janus kinase 1 (JAK1) can help reduce graft-versus-host-disease (GVHD) and cytokine release syndrome (CRS) while still retaining the benefits of graft-versus-leukemia (GVL) and improving engraftment.
Monoclonal Antibodies
Favezelimab + Pembrolizumab for Lymphoma
This trial will study the safety and effectiveness of two drugs, favezelimab and pembrolizumab, when used alone or in combination to treat people with classical Hodgkin lymphoma, diffuse large B-cell lymphoma, and indolent non-Hodgkin lymphoma.
CAR T-cell Therapy
Cytotoxic T Cells for Lymphoma
This trial is testing whether a new experimental therapy, third party LMP specific cytotoxic T lymphocytes (CTLs), can prevent or treat EBV Disorder including either Hodgkin Lymphoma or non-Hodgkin Lymphoma or Lymphoepithelioma or severe chronic active EBV infection syndrome (SCAEBV) or Leiomyosarcoma which has come back or has not gone away after treatment, including the best treatment.
CD30 Positive Clinical Trials
View 8 CD30 positive medical studies.
Monoclonal Antibodies
SGN-35T for Cutaneous T-Cell Lymphoma
This trial is looking at a type of cancer called lymphoma, which affects the blood cells that fight infections. The trial will enroll people with different types of lymphoma. The trial is testing a drug
CD20 Positive Clinical Trials
View 7 CD20 positive medical studies.
Chemotherapy
EPOCH + Rituximab for Lymphoma
This trial is testing whether reducing the amount of chemotherapy given to HIV-infected patients with non-Hodgkin's lymphoma will help rid the body of the lymphoma while decreasing the risk of infections and future cancers.
T-Cell Bispecific Antibody
Glofitamab + Obinutuzumab for Non-Hodgkin's Lymphoma
This trial is testing a new T-Cell bispecific (TCB), glofitamab, to see if it is safe and effective when used alone or in combination with obinutuzumab to treat patients with certain types of cancer. The trial is divided into 3 parts: dose escalation (Parts I and II) and dose expansion (Part III).
Monoclonal Antibodies
Atezolizumab + BTCT4465A (Mosunetuzumab) for Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
This trial is testing a new cancer drug, BTCT4465A (Mosunetuzumab), given alone or with another drug, atezolizumab. It is for people with B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia that has come back or does not respond to treatment.
Phase 3 Hodgkin's Lymphoma Clinical Trials
View 69 phase 3 hodgkin's lymphoma medical studies.
Acupuncture for Pain Management in Lymphoma
This trial will test whether adding acupuncture to usual pain management can reduce the amount of opioids needed to manage chemotherapy-induced pain, as well as study acupuncture's effects on other cancer treatment symptoms and quality of life.
Monoclonal Antibodies
R-mabHDI +1 More for Hodgkin's Lymphoma
Objective: The primary objective of the study is to evaluate the effect of R-mabHDI in patients with late stage, widespread stage and recurrent Lymphocytic Predominant Hodgkin's Lymphoma. The hypothesis is that the combination of R-mabHDI with the standard ABVD therapy in patients with late stage (Stage III and Stage IV) and recurrent stage Lymphocytic Predominant Hodgkin's Lymphoma will have a favorable outcome on the response and progress free survival. The study is also aimed at evaluating the safety of R-mabHDI . The aim of the study is to test this hypothesis by evaluating the clinical outcome in 1200 patients receiving combination of R-mabHDI once a week for 8 weeks and ABVD therapy every other week for 12 treatments.
Monoclonal Antibodies
Mosunetuzumab + Polatuzumab Vedotin for Aggressive B-Cell Lymphoma
This trial will compare the effectiveness of mosunetuzumab+polatuzumab vedotin to rituximab+gemcitabine+oxaliplatin in people with relapsed or refractory DLBCL, high-grade B-cell lymphoma, transformed follicular lymphoma, and FL3B.
Hodgkin's Lymphoma Clinical Trials With No Placebo
View 69 hodgkin's lymphoma medical studies that do not have a placebo group.
Janus Kinase Inhibitor
Itacitinib for Graft-versus-Host Disease Prevention
This trial is testing whether a drug that inhibits Janus kinase 1 (JAK1) can help reduce graft-versus-host-disease (GVHD) and cytokine release syndrome (CRS) while still retaining the benefits of graft-versus-leukemia (GVL) and improving engraftment.
Monoclonal Antibodies
Favezelimab + Pembrolizumab for Lymphoma
This trial will study the safety and effectiveness of two drugs, favezelimab and pembrolizumab, when used alone or in combination to treat people with classical Hodgkin lymphoma, diffuse large B-cell lymphoma, and indolent non-Hodgkin lymphoma.
Monoclonal Antibodies
Nivolumab + Brentuximab Vedotin for Hodgkin's Lymphoma
This trial will test whether nivolumab plus brentuximab vedotin is safe and effective in treating patients with Hodgkin's lymphoma who have relapsed or are refractory to first line treatment.
View More Hodgkin's Lymphoma Trials
See another 40 medical studies focused on hodgkin's lymphoma.
Frequently Asked Questions
Introduction to hodgkin's lymphoma
What are the top hospitals conducting hodgkin's lymphoma research?
When it comes to innovative clinical trials for Hodgkin's lymphoma, several esteemed hospitals are leading the way. In New york City, Memorial Sloan Kettering Cancer Center is at the forefront with six ongoing trials and an impressive history of 41 completed studies dedicated to understanding this complex condition. Since their first recorded trial in 1994, they have been committed to advancing knowledge and treatment options for patients. Meanwhile, Washington University School of Medicine in Saint Louis has emerged as a significant player in Hodgkin's lymphoma research as well. With four active trials and a total of 28 past studies under their belt since initiating their inaugural trial in 1997, they continue to contribute invaluable insights into this challenging disease.
In Omaha, Nebraska, the University of Nebraska Medical Center also stands out with its dedication to finding new solutions for Hodgkin's lymphoma. Like Washington University School of Medicine, they currently have four active trials underway and have conducted a commendable number of 22 previous studies since embarking on their first trial back in 1996.
Moving over to Milwaukee, Wisconsin - The Medical College is making strides with four ongoing clinical investigations focusing on Hodgkin's lymphoma while gaining valuable knowledge through eight previously held studies dating back only two decades from when it all began; that was marked by recording their very pioneering investigation on these cases which took place around2003.And last but certainly not least - MD Anderson Cancer Center located in Houston has also demonstrated its commitment by conducting four current hodgkins' lymphoma clinical tests while adding up sixteen more experiments from starting its investigative journey regarding these conditions merely eighteen years ago
These institutions serve as beacons of hope for individuals battling Hodgkin's lymphoma worldwide. Their relentless pursuit of answers through rigorous clinical trials offers promise for improved treatments and better outcomes for patients affected by this complex disease. Each step forward brings us closer to conquering Hodgkin's lymphoma once and for all.
Which are the best cities for hodgkin's lymphoma clinical trials?
When it comes to Hodgkin's lymphoma clinical trials, several cities in the United States stand out as hubs for innovative research. New york boasts 27 active trials studying treatments like CC-122 and JNJ-67856633. Houston, Texas follows closely with 25 ongoing studies focusing on MABEL CTLs and Antigen-Escalation Stage approaches. Meanwhile, Chicago, Los Angeles, and Denver also contribute significantly to the field with their respective 17, 16, and 15 active trials exploring various treatment options. These cities serve as crucial centers of advancement for individuals seeking cutting-edge therapies for Hodgkin's lymphoma.
Which are the top treatments for hodgkin's lymphoma being explored in clinical trials?
Exciting developments are underway in the field of Hodgkin's lymphoma research, with several cutting-edge treatments showing promise in ongoing clinical trials. Leading the pack is pembrolizumab, currently being explored in two active trials and having a total of 27 all-time studies dedicated to Hodgkin's lymphoma. Rituximab follows closely behind, also involved in two active trials and boasting an impressive 22 all-time clinical trials since its introduction in 1999. Another notable contender is EPOCH, with two ongoing trials focusing on this treatment option that first appeared on the scene back in 2009. Lastly, we have relatlimab—the newest addition to the lineup—currently under investigation in one active trial but already making waves as a potential game-changer for patients battling Hodgkin's lymphoma since its listing just this year (2022). These innovative therapies offer hope for improved outcomes and quality of life for individuals affected by this challenging disease.
What are the most recent clinical trials for hodgkin's lymphoma?
Recent clinical trials offer promising advancements in the treatment of Hodgkin's lymphoma. CAR-T cell therapy, a groundbreaking approach that harnesses the power of genetically modified immune cells, has shown potential in Phase 2 trials. Another study explores the use of anti-CD30 bispecific antibody-armed autologous T-cells to target and eliminate cancer cells—a hopeful development in Phase 1 and Phase 2 trials. Additionally, pembrolizumab demonstrates encouraging results as an immunotherapy option for patients with Hodgkin's lymphoma, while relatlimab shows promise as a treatment option during both Phase 1 and Phase 2 studies. Lastly, M+P (Arm A) is being evaluated through a large-scale Phase 3 trial to determine its efficacy in treating this form of lymphoma. With these innovative approaches paving the way forward, individuals battling Hodgkin's lymphoma can find solace in these advancements on their journey towards recovery.
What hodgkin's lymphoma clinical trials were recently completed?
Recent advancements in clinical trials for Hodgkin's lymphoma have paved the way for improved treatment options. In September 2019, ADC Therapeutics S.A. completed a trial investigating Camidanlumab Tesirine, an innovative therapy that shows promise against this type of cancer. Another significant milestone was reached in May 2018 when SCRI Development Innovations, LLC concluded their trial on Nivolumab, offering potential new avenues for patients with Hodgkin's lymphoma. Additionally, M.D. Anderson Cancer Center made notable progress with their study on Mycophenolate Mofetil, completing it in October 2017 and contributing valuable insights to enhance treatment strategies. These recent clinical trials demonstrate remarkable dedication from researchers worldwide as they strive to improve outcomes for individuals affected by Hodgkin's lymphoma.